Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 3/20 | 0.48 |
| ▸ | ADH1C | P00326 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9462350 | 0.98 | ADH1A (0.47) | ADH1AADH1CL3MBTL1MEN1KMT2A | |
| SCHEMBL13911314 | 0.96 | ADH1A (0.44) | ADH1AADH1CL3MBTL1MEN1KMT2A | |
| SCHEMBL18611275 | 0.90 | PIK3CD (0.43) | ADH1AADH1CL3MBTL1PIK3CDSLC6A2 | |
| SCHEMBL628951 | 0.89 | L3MBTL1 (0.42) | ADH1AADH1CL3MBTL1MEN1KMT2A | |
| SCHEMBL9632418 | 0.85 | THRA (0.43) | ADH1AADH1C | |
| SCHEMBL9632611 | 0.85 | THRA (0.43) | ADH1AADH1C | |
| SCHEMBL9812911 | 0.84 | PIK3CD (0.40) | ADH1AL3MBTL1MEN1KMT2APIK3CD | |
| SCHEMBL9837028 | 0.84 | ADH1A (0.48) | ADH1AADH1CL3MBTL1MEN1KMT2A | |
| SCHEMBL658992 | 0.83 | L3MBTL1 (0.50) | ADH1AADH1CL3MBTL1MEN1KMT2A | |
| SCHEMBL8903152 | 0.82 | ADH1A (0.47) | ADH1AADH1CL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | ADH1A 675/4885ADH1C 1487/4885L3MBTL1 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.